However, PP2A has been shown to be downregulated in the brains of AD patients promoting tau phosphorylation, and this effect is perhaps further compounded by translational inhibition of PTPA via miR-34a (Wei et al., 2020). The gene discussed is MAPT; the disease is Alzheimer disease.